Passivated Emitter and Rear Cells (PERC) are currently being introduced into mass production. The conversion efficiency of industrial p-type PERC cells is limited by the emitter saturation current density of around 90 fA/cm 2 of conventional homogeneously POCl 3 diffused emitters. In this paper we investigate two alternative emitter formation technologies. The first approach named in-situ oxidation inserts a short thermal oxidation in-between the phosphorus silicate glass deposition and the drive-in of a conventional homogeneous POCl 3 diffusion thereby reducing the phosphorus surface concentration. The second approach named Gas Phase Etch Back (GEB) selectively removes around 40 nm of the highly doped surface of the POCl 3 diffused emitter by the reactive gas phase of the wet chemical rear polishing bath. Whereas the conventional POCl 3 emitter exhibits a phosphorus surface doping concentration of 3 × 10 20 cm À3 , the in-situ oxidation and the GEB process reduce the doping concentration to 7 × 10 19 cm À3 and 4 × 10 19 cm À3 , respectively. Accordingly, the emitter saturation current density is reduced to excellent values of 22 fA/cm 2 (in-situ oxidation) and 28 fA/cm 2 (GEB) compared with 89 fA/cm 2 for the reference POCl 3 diffusion. Whereas the reference POCl 3 emitter limits the PERC conversion efficiency η to 21.1% and the open circuit voltage V oc to 655 mV, the in-situ oxidation improves the PERC current-voltage parameters up to 21.3% and 663 mV. The highest efficiency of 21.6% is obtained with the selective GEB emitter. When solving series resistance issues with the most advanced GEB emitter, the measured V oc and J sc values would support PERC conversion efficiencies up to 21.9%.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.